A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine
Conclusion This case report highlights the lack of financial transparency in the CREATE-X trial, and discusses the potential limitations that may exist in the current frameworks for disclosing financial ties between physicians and relevant industries in clinical trials. Achieving improved transparency is essential to heighten credibility in the findings of clinical trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Health Insurance | Insurance | International Medicine & Public Health | Investigational New Drugs | Japan Health | Legislation | Medical Devices | Men | Study | Xeloda